{
    "summary": "Vertex presents positive results at the European Association for the Study of Diabetes Annual Meeting on investigational treatment for type 1 diabetes - \n\n Our CRISPR/Cas9 gene-edited treatment for sickle cell disease and transfusion-dependent beta thalassemia is approved by the UK MHRA - \n\n Vertex announces Q3 2023 financial results - \n\n Vertex to share new data on investigational therapy for the treatment of sickle cell disease and beta thalassemia at the 2023 American Society of Hematology (ASH) Annual Meeting - \n\n We are presenting data on our fourth approved medicine for the treatment of cystic fibrosis at the 2023 North American Cystic Fibrosis Conference - \n\n New data shed light on health inequities in sickle cell disease - \n\n"
}